e-Therapeutics Board appoints Stephen Self to direct development
e-Therapeutics plc announced that Steve Self, Development Director, has agreed to join the Board as an Executive Director with immediate effect.
Steve began his career in Chemistry in 1975 with The Wellcome Foundation. He held a variety of positions in both R&D and Operations before being appointed as a full-time Project Manager in Wellcome Research in 1987. He became Head of Project management in 1991, and was appointed Group VP Project Management in 1993. Steve Joined Boots Healthcare International in 1995 as Head of Respiratory and Analgesic product development, before joining Merck Generics in 1997 as European Technical Director. He was appointed as Group R&D Director in 1999 and stayed with Merck until the sale of the company to Mylan in 2007. Since then he has worked for a private equity bank on major US pharmaceutical acquisitions.
Mr Self's primary responsibility will be to supervise the development of e-Therapeutics' proprietary portfolio of drug candidates. This involves complete Phase II trials of e-Therapeutics candidates in multiple metastatic cancers, depression and C.difficile plus possible Phase II trials for other anti-infective candidates. All the trials are planned to complete in 2012. Steve will use his considerable experience to deliver the trials and to ensure the highest quality data, suitable formulation, market positioning and the strongest intellectual property estate in each development project.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
